Cancer World Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
NEWSLETTER  |  PRINT VERSION
Facebook
Twitter
LinkedIn
Cancer World Magazine
Cancer World Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancer World Magazine > News > Link between COVID-19 and prostate cancer raises possibility of new treatments
  • News

Link between COVID-19 and prostate cancer raises possibility of new treatments

  • 13 July 2020
  • Janet Fricker
Illustration summarises potential drugs and vaccines for COVID-19 that target either host receptors, viral replication, virus assembly, or host immune response. Drugs that have been implicated in prostate cancer management (Degalerix, Anti-androgens, Glucocorticoid receptor antagonists, metformin, and rapamycin) appear in the blue lines. # Nasal Poly-ICLC (Hiltonol®), Oncovir Inc, is being investigated as a new therapeutic agent at Mount Sinai Source: D Chakravarty et al. Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. Commun Biol 3, 374 (2020). Reproduced under a Creative Commons licence
Link between COVID-19 and prostate cancer raises possibility of new treatments
Total
0
Shares
0
0
0
0
0
The overlapping biology identified between the molecular pathogenesis of COVID-19 and prostate cancer raises the possibility of repurposing drugs, including androgen deprivation therapy, for treating COVID-19, suggests a review in Nature Communications Biology, published 8 July. In the review the US authors additionally highlight the increased vulnerability of prostate cancer patients to COVID-19 and call for screening to be introduced. “The particular vulnerability of older men to COVID-19 compels us to advocate for routine screening of SARS-CoV-2 infections in prostate cancer patients,” write Dimple Chakravarty and colleagues from Icahn School of Medicine, at Mount Sinai, New York. The vulnerability of prostate cancer patients to COVID-19 is revealed by the authors own unpublished analysis, undertaken in the Mount Sinai Health System between March 1 2020 and April 26 2020. The study involved 9,648 COVID-19-positive patients, of whom 114 (2.2%) had been diagnosed with prostate cancer. Results revealed rates of intubation were greater for those diagnosed with prostate cancer than male patients with malignancies other than prostate cancer (25.4% vs 21.3%; P=0.02), and that mortality was greater for prostate cancer patients than male patients with other malignancies (23.7% vs 12.7%; P<0.01). Accumulating evidence, write the authors, suggests similarities between risk factors for COVID-19 and prostate cancer. “Older age and comorbidities (hypertension, diabetes, obesity, and smoking) that adversely affect COVID-19 are also lethal for prostate cancer,” they write. The authors draw attention to recent studies indicating that entry of SARS-CoV-2 (the virus causing COVID-19) into cells is through angiotensin-converting enzyme 2 (ACE2), and is also dependant on the serine protease activity of the TMPRSS2 gene (encoding for the transmembrane protease, serine 2). Studies indicate both ACE2 and TMPRSS2 may be under hormonal control, with higher levels of androgens signifying greater expression of these proteins, which could in turn increase vulnerability to COVID-19. Interestingly, an Italian study found that prostate cancer patients on androgen deprivation therapy were four times less likely to get infected with COVID-19 than prostate cancer patients not taking androgen deprivation therapy, and they were five times less likely to contract the disease compared to patients with other cancer types.
Illustration summarises potential drugs and vaccines for COVID-19 that target either host receptors, viral replication, virus assembly, or host immune response. Drugs that have been implicated in prostate cancer management (Degalerix, Anti-androgens, Glucocorticoid receptor antagonists, metformin, and rapamycin) appear in the blue lines. # Nasal Poly-ICLC (Hiltonol®), Oncovir Inc, is being investigated as a new therapeutic agent at Mount Sinai
Source: D Chakravarty et al. Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. Commun Biol 3, 374 (2020). Reproduced under a Creative Commons licence 4.0
The interconnectivity between COVID-19 and prostate cancer raises the possibility that prostate cancer therapies could be repurposed for COVID-19 patients, including use of anti-androgens and androgen deprivation therapies (ADT), and furthermore that TMPRSS2 protease inhibitors might provide alternative therapies. Trials are currently underway exploring use of the antiandrogen bicalutamide on COVID-19 in Baltimore, Maryland, and more than nine different clinical trials are looking at blocking enzymatic activity of TMPRSS2. In the review, the authors also consider the role of inflammation, with unpublished work by Chakravarty suggesting proinflammatory cytokines accelerate the progression of existing prostate cancer, with other studies showing that levels of IL-1 and IL-6 are associated with SARS-CoV-2 infection. “Systemic or tissue derived inflammation, during COVID-19, has the potential to accelerate pre-existing prostate cancer resulting in an aggressive phenotype and therefore represents a potential risk factor for prostate cancer patients,” write the authors.
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • covid-19
  • drug repurposing
  • prostate cancer
  • risk factors
Avatar
Janet Fricker

Previous Article
  • Articles
  • Biology basic

Malignant: Insights into the process of metastasis and how we can stop it

  • 10 July 2020
  • Adriana Albini
View Post
Next Article
  • Articles
  • Policy

On a mission to beat cancer

  • 17 July 2020
  • Sophie Fessl
View Post
You May Also Like
View Post
  • News

EC probe sets precedent for cancer drug price reduction

  • Janet Fricker
  • 1 March 2021
View Post
  • News

Study brings mass biparametric MRI screening for prostate cancer a step closer

  • Janet Fricker
  • 23 February 2021
View Post
  • News

Oncology providers urged to offer healthy life style advice to breast cancer survivors

  • Janet Fricker
  • 19 February 2021
View Post
  • News

Studies provide clarity on breast cancer genes for genetic panels

  • Janet Fricker
  • 9 February 2021
View Post
  • News

EC publishes route map for tackling cancer

  • Janet Fricker
  • 5 February 2021
View Post
  • News

Therapy targeting androgen receptors opens new chapter for hormone driven breast cancers

  • Janet Fricker
  • 27 January 2021
View Post
  • News

Coffee may protect against prostate cancer

  • Janet Fricker
  • 20 January 2021
View Post
  • News

Financial burden on older adults with advanced cancer worsens quality of life

  • Janet Fricker
  • 15 January 2021

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancer World archive
Latest news
  • EC probe sets precedent for cancer drug price reduction
    • 1 March 2021
  • Study brings mass biparametric MRI screening for prostate cancer a step closer
    • 23 February 2021
  • Oncology providers urged to offer healthy life style advice to breast cancer survivors
    • 19 February 2021
  • Studies provide clarity on breast cancer genes for genetic panels
    • 9 February 2021
  • EC publishes route map for tackling cancer
    • 5 February 2021
Latest printed issue
Article
  • Natural killers: a new tactical unit joins the cancer immunotherapy brigade
    • 25 February 2021
  • Immunotherapy toxicities demand a joined up approach from oncologists and organ specialists
    • 24 February 2021
  • Beating cancer is complex – our messaging must be clear
    • 11 February 2021
Newsletter

Don't miss our newsletter

Would you like to receive our bimonthly e-newsletter with the latest news from Cancer World magazine?

Subscribe now
Social

Would you follow us ?

Contents
  • Bridging the Age Gap in breast cancer: chemotherapy and quality of life
    • 2 March 2021
  • Moving towards efficiency in cancer care: Examples
    • 8 February 2021
  • World Cancer Day: we commemorate Professor Agim Sallaku
    • 3 February 2021
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancer World Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancer World is managed by SPCC Sharing Progress in Cancer Care | Piazza Indipendenza 2, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.